Apotex Granted Summary Judgment In US Pennsaid 2% Infringement Suit
Delaware District Court Case Involved Licensing Deal Signed In 2013
Apotex has decisively overcome Horizon’s patent infringement suit stemming from its launch of a generic version of the originator’s Pennsaid 2%.
You may also be interested in...
Unsatisfied with a US Court of Appeals upholding a ruling in favor of Teva's Actavis that several Pennsaid 2% patents were invalid, Horizon Therapeutics sought to have the case reheard en banc. However, the request has been refused.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.